

## CLAIMS

1. A hyperlipemia and/or hyperalbuminemia animal model comprising a transgenic non-human animal into which a regucalcin gene is introduced and which overexpresses regucalcin.
2. The hyperlipemia and/or hyperalbuminemia animal model according to claim 1, which is obtained by raising the transgenic non-human animal to the stage of senility (advanced age) at which it exhibits a symptom of hyperlipemia and/or hyperalbuminemia.
3. The hyperlipemia and/or hyperalbuminemia animal model according to claim 1, which is obtained by raising the transgenic non-human animal (female) until it exhibits a symptom of hyperalbuminemia.
4. The hyperlipemia and/or hyperalbuminemia animal model according to any one of claims 1 to 3, wherein the non-human animal exhibits a bone disorder at the stage of senility (advanced age).
5. The hyperlipemia and/or hyperalbuminemia animal model according to any one of claims 1 to 4, which is a homozygote.
6. The hyperlipemia and/or hyperalbuminemia animal model according to any one of claims 1 to 5, wherein the non-human animal is a rat.
7. The hyperlipemia and/or hyperalbuminemia animal model according to claim 6, wherein the stage of senility (advanced

age) means 36 to 50 weeks of age.

8. A method for using a transgenic non-human animal into which a regucalcin gene is introduced and which overexpresses regucalcin as an animal model for hyperlipemia and/or hyperalbuminemia.

9. The method according to claim 8, wherein the transgenic non-human animal is raised to the stage of senility (advanced age) and used as an animal model for hyperlipemia and/or hyperalbuminemia.

10. The method according to claim 8, wherein the transgenic non-human animal (female) is raised until it exhibits a symptom of hyperalbuminemia and used as an animal model for hyperlipemia and/or hyperalbuminemia.

11. The method according to any one of claims 8 to 10, wherein the non-human animal exhibits a bone disorder at the stage of senility (advanced age).

12. The method according to any one of claims 8 to 11, which is a homozygote.

13. The method according to any one of claims 8 to 12, wherein the non-human animal is a rat.

14. The method according to claim 13, wherein the stage of senility (advanced age) means 36 to 50 weeks of age.

15. A method for screening a therapeutic drug for hyperlipemia and/or hyperalbuminemia comprising the steps of; administering a test substance to the hyperlipemia and/or hyperalbuminemia animal model according to any one of claims 1 to 7, and measuring/evaluating the amount of lipid and/or albumin in blood.

16. A method for screening a preventive drug for hyperlipemia and/or hyperalbuminemia comprising the steps of; administering a test substance to the hyperlipemia and/or hyperalbuminemia animal model according to any one of claims 1 to 7 before it reaches the stage of senility (advanced age) at which it exhibits a symptom of hyperlipemia and/or hyperalbuminemia, and measuring/evaluating the amount of lipid and/or albumin in blood after it reaches the stage of senility (advanced age).